NCT03013218: A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma

NCT03013218
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known symptomatic CNS metastases or lepotomeningeal disease requiring steroids.
https://ClinicalTrials.gov/show/NCT03013218

Comments are closed.

Up ↑